MindMed Activist Investor Moves To Take Control Of Board

MindMed (NASDAQ: MNMD) has seen its activist investor file a preliminary proxy statement for its proposed set of directors after the firm indicated last year it intended to work to take control of the company. The activist investor, FCM MM Holdings, is ran by a former co-founder of MindMed, Dr Scott Freeman.

Describing itself as “one of MindMed’s largest investors,” the firm has just a 3.5% stake in the company, yet is attempting to exert control. FCM proposed a total of four directors for the firms board, including Dr Scott Freeman, co-founder of MindMed and former Chief Medical Officer, Dr Farzin Farzaneh, a professor of molecular medicine at King’s College London, Vivek Jain, a venture capitalist, and Alexander Wodka, a former partner at Crowe.

In announcing that the filing has been made, FCM highlighted that MindMed has seen its shares decline 89% over the past year, despite its peer group falling on average 62%.

The firm also addressed recent comments by MindMed wherein the company referred to FCM as not having paid a “control premium,” which FCM claims is “simply mendacious,” given the fact that they are not seeking a buy out (they just want control instead). FCM claims that they are simply looking to repair operational challenges and restore shareholder value.

“Since 2021, I have been proactively engaging the Board about the delays in the MM-110 and MM-120 programs. Unfortunately, these entreaties were ignored, and subsequently, management botched the MM-110 program while the MM-120 program is over a year behind schedule due to a myriad of operational failures. As a result, I believe the only path forward for MindMed is an immediate reconstitution of the Board,” commented Freeman.

MindMed last traded at $3.81 on the Nasdaq.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Silver Is in a New Price Regime, and the Market Isn’t Used to It | Keith Neumeyer – First Majestic

Agnico Eagle Just Made a Massive Gold Land Grab

A Copper-Gold Deposit Caught the White House’s Attention | Rob McLeod – Cambria Gold

Recommended

Mercado Drills 256 g/t Silver Over 6.5 Metres In First Drill Hole of Inaugural Program

Antimony Resources Drills 4.38% Sb Over 7.05 Metres At Bald Hill In Final Hole Of 2025 Program

Related News

Shroom Progress! MindMed Advances Towards a Phase 2 LSD Microdosing Trial For Adult ADHD

Aftermarket MindMed (NEO:MMED) announced they entered into a clinical trial agreement with Maastricht University to...

Monday, May 11, 2020, 10:29:04 PM

Mind Medicine To Raise Further $19.5 Million In Bought Deal

Mind Medicine (NEO: MMED) this morning announced that it is conducting yet another round of...

Monday, March 8, 2021, 07:59:24 AM

MindMed Launches Psychedelic-Based Pain Treatment Project

Mind Medicine Inc. (NEO: MMED), also known as MindMed, announced today that it has launched...

Wednesday, May 5, 2021, 09:44:00 AM

Mind Medicine Sees FDA Place Clinical Hold On Phase 2b Study

Mind Medicine (NEO: MMED) this morning indicated that things are not going quite to plan...

Tuesday, December 21, 2021, 08:22:51 AM

MindMed Sees Positive Results For Its LSD Treatment For Anxiety Disorders Published In Peer-Reviewed Journal

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced on Thursday that the...

Thursday, September 8, 2022, 05:03:00 PM